Attaining at least 5% average annual sales growth in terms of volume/value, allocating 10% of revenues to research and development, and achieving an average EBITDA margin of at least 25% are among a raft of key strategic objectives that Krka Group has laid out to the year 2026, following publication of its nine-month financial results and 2022 group business plan.
The Slovenian firm also desires to enter new therapeutic classes and specialties as an “innovative generic company,” and develop complex...
